Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide

References

• Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341–1348.
   PubMed Web of Science ®Google Scholar
• Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852–3860.
   PubMed Web of Science ®Google Scholar
• Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89: 3354–3360.
   Google Scholar
• Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505–2515.
   PubMed Web of Science ®Google Scholar
• Lengfelder E, Hofmann WK, Nowak D. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia 2012;26: 433–442.
   PubMed Web of Science ®Google Scholar
• Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107:2627–2632.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhang Y, Li J, et al. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood 2010;115:1697–1702.
   PubMed Web of Science ®Google Scholar
• Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: longterm follow-up data. J Clin Oncol 2010;28: 3866–3871.
   PubMed Web of Science ®Google Scholar
• Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 2011;29:2753–2757.
   PubMed Web of Science ®Google Scholar
• Emadi A, Gore SD. Arsenic trioxide - an old drug rediscovered. Blood Rev 2010;24:191–199.
   PubMed Web of Science ®Google Scholar
• Zhou J, Meng R, Yang BF. Comparing two arsenic trioxide administration methods in APL therapy. Chin Med J (Engl) 2004;117:1411–1413.
   PubMed Web of Science ®Google Scholar
• Zhou J, Meng R, Li X, et al. The effect of arsenic trioxide on QT interval prolongation during APL therapy. Chin Med J (Engl) 2003;116:1764–1766.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhou J, Lu X, et al. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem Res Toxicol 2004, 17:95–103.
   PubMed Web of Science ®Google Scholar
• Chen GQ, Zhou L, Styblo M, et al. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res 2003;63:1853–1859.
   PubMed Web of Science ®Google Scholar
• Fukai Y, Hirata M, Ueno M, et al. Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine. Biol Pharm Bull 2006;29:1022–1027.
   PubMed Web of Science ®Google Scholar
• Fujisawa S, Ohno R, Shigeno K, et al. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. Cancer Chemother Pharmacol 2007;59:485–493.
   PubMed Web of Science ®Google Scholar
• Yoshino Y, Yuan B, Miyashita SI, et al. Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. Anal Bioanal Chem 2009;393: 689–697.
   PubMed Web of Science ®Google Scholar
• Kiguchi T, Yoshino Y, Yuan B, et al. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leuk Res 2010;34:403–405.
   PubMed Web of Science ®Google Scholar
• Iriyama N, Yoshino Y, Yuan B, et al. Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient. J Hematol Oncol 2012;5:1.
   PubMed Web of Science ®Google Scholar
• Slejkovec Z, Falnoga I, Goessler W, et al. Analytical artefacts in the speciation of arsenic in clinical samples .Anal Chim Acta 2008;607: 83–91.
   PubMed Web of Science ®Google Scholar
• Jesus JP, Suárez CA, Ferreira JR, et al. Sequential injection analysis implementing multiple standard additions for As speciation by liquid chromatography and atomic fluorescence spectrometry (SIA-HPLC-AFS). Talanta 2011;85:1364–1368.
   PubMed Web of Science ®Google Scholar
• Duzkale H, Jilani I, Orsolic N, et al. In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines. Cancer Chemother Pharmacol 2003;51:427–432.
   PubMed Web of Science ®Google Scholar
• Falnoga I, Slejkovec Z, Pucer A, et al. Arsenic metabolism in multiple myeloma and astrocytoma cells. Biol Trace Elem Res 2007;116:5–28.
   PubMed Web of Science ®Google Scholar
• Charoensuk V, Gati WP, Weinfeld M, et al. Differential cytotoxic effects of arsenic compounds in human acute promyelocytic leukemia cells. Toxicol Appl Pharmacol 2009;239:64–70.
   PubMed Web of Science ®Google Scholar
• Liu Y, Hock JM, Sullivan C, et al. Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation. J Cell Biochem 2010;111:1546–1555.
   PubMed Web of Science ®Google Scholar